A new post-hoc analysis set for presentation at ECO 2026 will examine the efficacy and safety of orforglipron in adults aged 65 and older, stratified by obesity with and without type 2 diabetes. The study will evaluate how the oral GLP-1 receptor agonist performs in an age group that can differ meaningfully in pharmacodynamics and tolerability, with trial-style results expected at the congress.